Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry

Linda Baughn, Zohar Sachs, Klara E. Noble-Orcutt, Amit Mitra, Brian G. Van Ness, Michael A. Linden

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3–4-fold. Here, we compared FBC and MC in the immunophenotypic characterization of Bz-sensitive and -resistant human MM cell line U266. We show that Bz-resistant cells are associated with the loss of CD56 and CD66a adhesion molecules as well as an activation signature.

Original languageEnglish (US)
Pages (from-to)1931-1940
Number of pages10
JournalLeukemia and Lymphoma
Volume58
Issue number8
DOIs
StatePublished - Aug 3 2017

Fingerprint

Multiple Myeloma
Flow Cytometry
Cell Line
Fluorescence
Plasma Cell Neoplasms
Heavy Ions
Proteasome Inhibitors
Heavy Metals
Treatment Failure
Drug Resistance
Epitopes
Mass Spectrometry
Bortezomib
Antibodies

Keywords

  • bortezomib
  • cytometry
  • drug resistance
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. / Baughn, Linda; Sachs, Zohar; Noble-Orcutt, Klara E.; Mitra, Amit; Van Ness, Brian G.; Linden, Michael A.

In: Leukemia and Lymphoma, Vol. 58, No. 8, 03.08.2017, p. 1931-1940.

Research output: Contribution to journalArticle

Baughn, Linda ; Sachs, Zohar ; Noble-Orcutt, Klara E. ; Mitra, Amit ; Van Ness, Brian G. ; Linden, Michael A. / Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry. In: Leukemia and Lymphoma. 2017 ; Vol. 58, No. 8. pp. 1931-1940.
@article{7f1368a7bda348dcaa470ef8766a7f8c,
title = "Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry",
abstract = "Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3–4-fold. Here, we compared FBC and MC in the immunophenotypic characterization of Bz-sensitive and -resistant human MM cell line U266. We show that Bz-resistant cells are associated with the loss of CD56 and CD66a adhesion molecules as well as an activation signature.",
keywords = "bortezomib, cytometry, drug resistance, Multiple myeloma",
author = "Linda Baughn and Zohar Sachs and Noble-Orcutt, {Klara E.} and Amit Mitra and {Van Ness}, {Brian G.} and Linden, {Michael A.}",
year = "2017",
month = "8",
day = "3",
doi = "10.1080/10428194.2016.1266621",
language = "English (US)",
volume = "58",
pages = "1931--1940",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry

AU - Baughn, Linda

AU - Sachs, Zohar

AU - Noble-Orcutt, Klara E.

AU - Mitra, Amit

AU - Van Ness, Brian G.

AU - Linden, Michael A.

PY - 2017/8/3

Y1 - 2017/8/3

N2 - Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3–4-fold. Here, we compared FBC and MC in the immunophenotypic characterization of Bz-sensitive and -resistant human MM cell line U266. We show that Bz-resistant cells are associated with the loss of CD56 and CD66a adhesion molecules as well as an activation signature.

AB - Multiple myeloma (MM) is an incurable malignant plasma cell neoplasm. Proteasome inhibitors including Bortezomib (Bz) are used to treat MM, and treatment failure due to drug resistance occurs. Bz-sensitive and -resistant MM cells have distinct immunophenotypic signatures that correlate with clinical outcome. These changes can be identified by fluorescence-based cytometry (FBC), however, FBC is rarely used in predicting Bz resistance. Mass cytometry (MC) is a recently developed variation of flow cytometry that detects heavy metal-ion tagged antibodies using time-of-flight mass spectrometry allowing for detection of up to 38 epitopes simultaneously in a single cell, without significant overlap, exceeding the dimensionality of FBC 3–4-fold. Here, we compared FBC and MC in the immunophenotypic characterization of Bz-sensitive and -resistant human MM cell line U266. We show that Bz-resistant cells are associated with the loss of CD56 and CD66a adhesion molecules as well as an activation signature.

KW - bortezomib

KW - cytometry

KW - drug resistance

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85006307292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006307292&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1266621

DO - 10.1080/10428194.2016.1266621

M3 - Article

VL - 58

SP - 1931

EP - 1940

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -